Documente Academic
Documente Profesional
Documente Cultură
Fiziopatologia pneumopatiilor
interstiiale difuze
Ovidiu Fira-Mladinescu
1. Disciplina de Pneumologie
Universitatea de Medicin i Farmacie Victor Babe
Timioara
2. Clinica Universitar de Pneumologie,
Compartimentul de Recuperare Medical Respiratorie
Spitalul Clinic de Boli Infecioase i Pneumoftiziologie
Victor Babe Timioara
AGENDA
1. Mecanismele moleculare i conceptele fiziopatologice din
fibroza
pulmonar
ntr-o
PERSPECTIV
CLINICOTERAPEUTIC
Model patogenic actual
Factori de risc
Fumatul
Noxe inhalatorii
Infecii virale
Refluxul gastro-esofagian
Predispoziia genetic
4
Downey G, ERS Annual Congress, Barcelona 2013
Drugs
Infections-viruses
Radiation
Other diseases
Intact
Wound healing
Aberrant
Genetic
predisposition
Lung homeostasis
6
Wuyts WA et al, Eur Respir J, 2013; 41:1207-1218
8
Maher TH, Clin Chest Med, 2012; 33(1): 69-83
Tanjore H et al, Am J Physiol Lung Cell Mol Physiol, 2012; 302: L721-L729
Hidenori Kage and Zea Borok, Curr Opin Pulm Med, 2012; 18(5): 517523
11
Gharace-Kermani M et al, Pharm Res, 2007; 33(1): 69-83
PARADOXUL APOPTOTIC
12
Thannickal VJ and Horowitz JC, Proc Am Thorac Soc, 2006; 3:350-356
Ahluwalia N, et al. Am J Respir Crit Care Med. 2014 Aug 4. [Epub ahead of print].
14
Molyneaux PL and Maher TM, Eur Respir Rev, 2013; 22:376-381
15
Lawson WE et al, Am J Physiol Lung Cell Mol Physiol , 2008; 294: L1119-L1126
Terapia antiviral
Refluxul Gastro-Esofagian
1. Prevalena RGE in FPI este estimat pn la 90%
(Rangu G et al, Eur Respir J, 2006, 27:136-142)
Fumatul i FPI
18
Carroz KP et al, Arch Bronconeumol, 2010; 46(12):646-651
19
Lawson WE et al, Am J Med Sci, 2011; 341(6):439-443
21
Tanjore H et al, Am J Physiol Lung Cell Mol Physiol , 2012; 302: L721-L729
Predispoziia genetic
Biomarkeri pentru FP
Candidai
chemokina CCL18
LOXL2
complexul telomerazic
proteinele surfactantului A & D
KL-6
Matrix Metallo-Proteases (MMP1/MMP7)
Fibrocitele circulante
Parametrii clinici
nc nevalidai i disponibili n puine centre
Cumulative Survival
P < 0.001
Cumulative Incidence
Probability
Composite Disease
Progression Endpoint
(ARTEMIS Cohort)*
Time Months
DLco
26
Valori bazale
100
*
% din prezis
80
60
40
20
0
CVF
CPT
27
VR
DLco
DLco/VA
9,23
% prezis
19,23
71,54
90
80
70
60
50
40
30
20
10
0
78,42
71,3
45,28 45,95
CVF
DLco
28
29
Tablou funcional
Fibroz pulmonar
Emfizem centrolobular
Fibroz pulmonar
Hipertensiune pulmonar
Disfuncie restrictiv
30
Tablou funcional
Fibroz pulmonar
Restricie
extraparenchimatoas
Hipertensiune pulmonar
Restricie
extraparenchimatoas
31
32
TESTS/
CLINICAL
FACTORS
FVC
DLCO
6MWT
PREDICTIVE VALUE
Pulmonary
hypertension
Dyspnea score
Hospitalization
Survival
80 80
e n t s u r v iv a l
P e r cPercent
P e r c e n t s u r v iv a l
1 0 01 0 0
60 60
40 40
P=0.0053
20 20
0
0
01 2 1 22 4 2 43 6 3 64 8 4 86 0 6 07 2 7 28 4 8 49 6 9160 81 01 82 01 2 0
M oM
n tohnst h s
Months
80
80
Survival
n t s u r v iv a l
P e r c ePercent
P e r c e n t s u r v iv a l
100
100
60
60
40
40
P=0.0001
20
20
0
0 0 12 24 36 48 60 72 84 96 108 120
0
1 2 2 4 3 6 M 4o8n t h6 s0 7 2 8 4 9 6 1 0 8 1 2 0
M o n th s
Months
Nathan SD, et al. Chest. 2011;140:221-229.
RR
95%
50
3.90
1.49-10.19
0.006
51-65
2.35
1.18-4.78
0.016
3.65
2.03-6.57
<0.001
5 9.9
1.95
1.24-3.09
0.004
1.74
1.10-2.99
0.046
35
2.41
1.19-4.87
0.015
Survival Probability
> 13bpm
HR 1 minute
after 6MWT
13bpm
Survival Probability
Days of Follow-Up
Baseline 6MWT
distance
Time Weeks
P = 0.01
6MWT distance
at 24 weeks
Time Weeks
du Bois RM, et al. Eur Respir J. 2014;43(5):1421-1429.Swigris JJ, et al. Chest. 2009;136:841-848
P < 0.001
2,65*
3
2
1,54
1
1
0
350
250-349
distanta TM6' (m)
38
< 250
RR, mortalitate la 1 an
RR, mortalitate la 1 an
4,27*
3,59*
4
3
2
1
0
< 50
25-50
> 50
TESTS/ CLINICAL
FACTORS
Study Inclusion
Criteria
Study Endpoint
DLCO
6MWT
Pulmonary hypertension
FVC
Dyspnea score
Hospitalization
40
Criteriile ghidului
International Society for Heart and Lung Transplantation
Referirea pacientului Evidene imagistice sau histopatologice de UIP
ctre un centru de indiferent de valoarea CVF
transplant
Evidene histopatologice de NSIP de tip fibros
CONCLUZII
FPI apare dup injurii repetate ale epiteliului
alveolar la indivizii predispui genetic, la care
rspunsul reparator tisular este disfuncional
determinnd
o
alterare
arhitectural
a
parenchimului pulmonar.
nelegerea
mecanismelor
fiziopatologice
caracteristice FPI ar putea duce la apariia unor
noi abordri terapeutice ale acestei boli care
actualmente are un prognostic infaust.
CONCLUZII
Anumite forme de PID au tablouri funcionale
caracteristice i de aceea evaluarea funcional
pulmonar
poate
avea
implicaii
asupra
diagnosticului diferenial.
Evaluarea funcional pulmonar constituie cel mai
acurat mijloc de cuantificare a severitii, precum i
de monitorizare a evoluiei PID .
43
V MULUMESC!
45
EFP - Spirometrie
46
EFP - DLco
47
EFP - Spirometrie
49
EFP - DLco
50
Sindrom Raynau de
aproximativ 1 an, ulceratii
cutante periungheale,
poliartralgii
VSH, fibrinogen
Ac antinucleari +
Profil ANA pozitiv:
Ac anti ScL70 +++
HRCT: aspect normal
Echocardiografie: PAPs
normala
51
EFP - Spirometrie
52
EFP - DLco
53
CVF = 26,2%
55
DLco = 32,6%
56